Top

Published in:

01-12-2013 | Research Article

A systematic review of p53 as a biomarker of survival in patients with osteosarcoma

Authors: Hai-Liang Fu, Lin Shao, Qiang Wang, Tao Jia, Ming Li, Da-Ping Yang

Published in: Tumor Biology | Issue 6/2013

Abstract

Osteosarcoma is the most common malignant bone tumor, and the prognosis of patients with osteosarcoma is still unsatisfactory with low survival rates. There are many studies assessing the prognostic role of upregulated p53 in patients presenting osteosarcoma, and there is no consistent finding. To summarize the existing evidence about whether the presence of upregulated p53 was a biomarker of survival in patients with osteosarcoma, we performed a systematic review and meta-analysis of relevant publications. We assessed the effect of upregulated p53 on the 3-year overall survival and the 3-year disease-free survival by calculating the pooled odds ratio (OR) with corresponding 95 % confidence interval (95 %CI). Fifteen studies with a total of 609 patients with osteosarcoma were finally included into the systematic review and meta-analysis. Compared with osteosarcoma patients with low or undetectable p53, patients with upregulated p53 were obviously associated with decreased 3-year overall survival (OR = 0.29, 95 %CI 0.19–0.43, P < 0.001). In addition, patients with upregulated p53 were obviously associated with decreased 3-year disease-free survival (OR = 0.06, 95 %CI 0.02–0.23, P < 0.001). The results from the systematic review and meta-analysis highlight that p53 is an effective biomarker of survival in patients with osteosarcoma. In addition, more studies with a large sample size are needed to identify the effect of p53 expression in osteosarcoma patients.

Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137–9.PubMed

Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85–92.PubMedCrossRef

Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008;7:3461–9.PubMedCrossRef

Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247–63.PubMedCrossRef

Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670–8.PubMedCrossRef

Ye ZM, Li WX, Fan SW, Yang DS, Tao HM. Expression of p53 protein and proliferating cell nuclear antigen (PCNA) in osteosarcoma and its prognostic significance [article in Chinese]. Zhejiang Med J. 2000;22:65–7.

Zhang L, Yang ZY, Tang RY, Mei J, Ai ZS. The relationship with the protein expression of p53, pten and the three-year survival ratios in osteosarcoma patients [article in Chinese]. J Pract Radiol. 2003;19:673–6.

Wu X, Chen ZR, Zhang GJ. [Apoptosis-related gene expression and its clinical significance of human osteosarcoma]. Zhonghua Zhong Liu Za Zhi. 2004;26:678–81.PubMed

Bao Y, Li HP, Fan R, Jiang C. Expression of p53 protein in osteosarcoma and its significance [article in Chinese]. Acta Acad Med CPAPF. 2006;15:230–1.

10.

Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M, et al. The expression and significance of idh1 and p53 in osteosarcoma. J Exp Clin Cancer Res. 2010;29:43.PubMedCrossRef

11.

Zhang SQ, Xiao DM, Zhu YH, Guan H, Li W, Tan JF. Protein expression of p53 in osteosarcoma and the correlation with clinical features and prognosis [article in Chinese]. J Mod Oncol. 2011;19:145–6.

12.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef

13.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

14.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

15.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef

16.

Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150:237–42.PubMedCrossRef

17.

Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100:1936–42.PubMedCrossRef

18.

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781–8.PubMed

19.

Kaseta MK, Khaldi L, Gomatos IP, Tzagarakis GP, Alevizos L, Leandros E, et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol. 2008;97:259–66.PubMedCrossRef

20.

Oliveira CR, Mendonca BB, Camargo OP, Pinto EM, Nascimento SA, Latorre Mdo R, et al. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters. Clinics (Sao Paulo). 2007;62:167–74.CrossRef

21.

Ozger H, Eralp L, Atalar AC, Toker B, Esberk Ates L, Sungur M, et al. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis]. Acta Orthop Traumatol Turc. 2009;43:28–34.PubMedCrossRef

22.

Papai Z, Feja CN, Hanna EN, Sztan M, Olah E, Szendroi M. P53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas. Pathol Oncol Res. 1997;3:15–9.PubMedCrossRef

23.

Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, Iijima T, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract. 2000;196:665–73.PubMedCrossRef

24.

Wu X, Cai ZD, Lou LM, Zhu YB. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol. 2012;36:212–6.PubMedCrossRef

25.

Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009;9:714–23.PubMed

26.

Vousden KH, Ryan KM. P53 and metabolism. Nat Rev Cancer. 2009;9:691–700.PubMedCrossRef

27.

Silva JL, Vieira TC, Gomes MP, Bom AP, Lima LM, Freitas MS, et al. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res. 2010;43:271–9.PubMedCrossRef

28.

Fan C, Lin X, Wang E. Clinicopathological significance of cathepsin d expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study. Tumour Biol. 2012;33:1045–52.PubMedCrossRef

29.

Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, et al. Alterations of tp53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328–38.PubMedCrossRef

30.

Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, et al. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur Respir J. 2012;40:177–84.PubMedCrossRef

Title: A systematic review of p53 as a biomarker of survival in patients with osteosarcoma
Authors: Hai-Liang Fu
Lin Shao
Qiang Wang
Tao Jia
Ming Li
Da-Ping Yang
Publication date: 01-12-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0966-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Cultivation-dependent plasticity of melanoma phenotype

Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221

Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis

Regulation of BMI1 Polycomb gene expression in histological grades of invasive ductal breast carcinomas and its correlation with hormone receptor status

Association between tumor necrosis factor β 252 A/G polymorphism and risk of gastric cancer: a meta-analysis

Association of the MTHFR C677T polymorphism with primary brain tumor risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer